Introduction: Total PSA (tPSA) and free PSA (fPSA) are the most commonly used biomarkers for early detection of prostate cancer. Despite standardization efforts, many available PSA assays may still produce discordant results. In the present study, we compared four PSA assays calibrated to the WHO standards 96/670 and 96/668 for tPSA and fPSA, respectively.
Methods: Within the scope of the Prostate Cancer Early Detection Study Based on a ''Baseline'' PSA Value in Young Men (PROBASE), we tested tPSA and fPSA in serum samples from 50 patients in the four different PROBASE sites using four WHO-calibrated assays from Roche (Elecsys, Cobas), Beckman-Coulter (Access-II) and Siemens (ADVIA Centaur). The comparison was performed using the Passing-Bablok regression method.
Results: Compared to Access, the median tPSA levels for Centaur, Elecsys, and Cobas were +3%, +11%-20%, and +17%-23%, respectively, while for median fPSA levels the differences for Centaur, Elecsys, and Cobas were +49%, +29%-31%, and +22%, respectively.
Discussion: Despite all investigated assays being WHO-calibrated, the Elecsys and Cobas tPSA assays produced considerably higher results than the Access and Centaur assays. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 μg/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 μg/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1724600818754750 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term.
Neurology
January 2025
Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Background And Objectives: Blood-based biomarkers of amyloid and tau have been shown to predict Alzheimer disease (AD) dementia. Much less is known about their ability to predict risk of mild cognitive impairment (MCI), an earlier disease stage. This study examined whether levels of blood biomarkers of amyloid (Aβ/Aβ ratio), tau (p-tau), neurodegeneration (NfL), and glial activation and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) collected when participants were cognitively normal are associated with the time to onset of MCI.
View Article and Find Full Text PDFEvaluation of Siemens Atellica AMH assay and comparison with Roche, Beckman and Ansh Labs.
Clin Biochem
January 2025
Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH, USA. Electronic address:
Background: Anti-Müllerian hormone (AMH) is an important marker for ovarian reserve and response to fertility treatments. However, interassay variability exists due to the lack of a standardized method. This study evaluates the performance of the new Siemens Healthineers Atellica IM AMH assay against established assays (Beckman DxI 600 Access, Roche cobas Elecsys® e801, and Ansh Labs AMH ELISA).
View Article and Find Full Text PDFThe frequency of macroprolactinemia among patients with hyperprolactinemia in a central laboratory of a training and research hospital.
North Clin Istanb
November 2024
Department of Medical Biochemistry, Goztepe Prof. Dr. Suleyman Yalcin Training and Research Hospital, Istanbul, Turkiye.
Objective: Macroprolactinemia is a well-described endocrine disorder, with its results leading to unnecessary tests and overtreatment. However, routine macroprolactin screening is not performed in many laboratories. Routinely used prolactin assays can result in false diagnosis of hyperprolactinemia in patients with no signs and symptoms related to hyperprolactinemia and clinicians should be aware of macroprolactinemia frequency encountered with the method in use.
View Article and Find Full Text PDFProspective appraisal of clinical diagnostic algorithms for hepatocellular carcinoma surveillance in Chinese patients with chronic hepatitis B infection.
Sci Rep
November 2024
Clinical Development and Medical Affairs, Roche Diagnostics International AG, Rotkreuz, Switzerland.
Hepatocellular carcinoma (HCC) is often detected at advanced stages among patients with hepatitis B virus (HBV), underscoring the urgency for more precise surveillance tests. Here, we compare the clinical performance of the novel - GAAD (gender [biological sex], age, alpha-fetoprotein [AFP], protein-induced by vitamin K absence-II [PIVKA-II]) and GALAD (gender [biological sex], age, AFP, Lens-culinaris AFP [AFP-L3]), PIVKA-II) algorithms to assess the utility of AFP-L3 for distinguishing HCC from benign chronic liver disease (CLD) in Chinese patients with predominantly chronic HBV infection. Eligible adults were enrolled, and biomarkers were measured using Elecsys (Cobas) or µTASWAKO assays.
View Article and Find Full Text PDFBackground: Vitamin D is a fat-soluble vitamin found in two forms, sourced either from plants (D2) or animals (D3). Numerous epidemiological studies worldwide have highlighted its deficiency across diverse populations in various countries. When coupled with obesity, this deficiency becomes a significant global health concern.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!